They are not looking to get high, they are using something that...

They are not looking to get high, they are using something that has known qualities and are looking to see if those same qualities are even better with TPM, whist not increasing some of the side effects when using an increase in CBD.

"Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168 avecho.com.au
While the increased bioavailability produced by formulations containing TPM® is important, it was equally significant that the increase in absorption from TPM® formulations did not produce any observable GI issues.
Increasing the dose of CBD products, including Epidiolex®, can cause diarrhea and GI distress. This GI
irritation can be prohibitive for indications requiring high doses of CBD, and industry has been looking for a way to increase the CBD dose without increasing the associated irritation. Dogs are an especially sensitive model for the assessment of GI irritation. No GI irritation was observed for the Avecho formulation or the Epidiolex + TPM® in dogs, despite the four-fold increase in CBD absorption. TPM® formulations may therefore be appropriate in the future for indications that require very high doses of CBD.
The increased absorption of the Avecho CBD formulation versus controls has now reproduced across two independent animal models; rodent and dog. These results validate the Company’s choice of formulation for use in human trials seeking low dose CBD approval, and gives the product maximal chance of success in the upcoming Phase III.

Market Opportunity:
The performance of the Epidiolex +TPM® formulation is especially noteworthy, as it demonstrates that
TPM® may be added to further products to increase their effectiveness. At a time when CBD and cannabis are rapidly becoming a simple commodity, differentiation of products will be key to maintain brand position.
The medicinal and consumer CBD market is expected to grow from around AU$8B (2019) to greater than AUS$25B in 2025. While the market continues to expand, the lack of differentiation between products has already become apparent. A rapidly changing regulatory environment, including the possibility of over-the-counter CBD in Australia, further compounds the limitations associated with existing medicinal cannabis dosage forms.
A growing number of companies are now looking for ways to formulate and commercially differentiate their medicinal cannabis products. Cannabinoid products with enhanced absorption, such as those identified in our recent animal studies, could offer significant therapeutic benefits to patients with commensurate commercial benefits to Avecho and its partners.
In alignment with this, Avecho has recently begun formal business development outreach to the larger
recreational cannabis space in North America, with this new data to be a feature of these discussions.